G-1 (CAS 881639-98-1): A Selective GPR30 Agonist Transforming Neuro-Cardio Research

Principle & Setup: Harnessing G-1 for GPR30 Pathway Dissection

G-1, a potent and selective G protein-coupled estrogen receptor (GPR30/GPER1) agonist, enables researchers to interrogate rapid, non-genomic estrogen signaling with exceptional specificity. With a binding affinity (Ki) of ~11 nM and negligible off-target activity toward classical estrogen receptors even at micromolar doses, G-1 (SKU B5455) is engineered for high-precision experimental applications (product_spec). Its efficacy is underpinned by rapid induction of intracellular calcium flux (EC50 ≈ 2 nM) and PI3K-dependent nuclear PIP3 accumulation, making it a cornerstone for studies in cardiovascular adaptation, breast cancer cell migration, and neuropathic pain signaling (paper).

Step-by-Step Workflow: Optimizing G-1 Protocols for Reliable Data

To achieve reproducible outcomes with G-1, careful attention to preparation, dosing, and application is essential. The following workflow, validated in both in vitro and in vivo models, ensures robust GPR30 activation:

1. Stock Preparation: Dissolve G-1 in DMSO at >10 mM. Due to its insolubility in water and ethanol, warming and brief ultrasonic treatment are recommended to fully dissolve the crystalline solid (product_spec).
2. Aliquoting & Storage: Prepare small aliquots to avoid freeze-thaw cycles. Store at -20°C and use promptly to minimize compound degradation (workflow_recommendation).
3. Cell Assays: For migration or signaling assays (e.g., in SKBr3 or MCF7 breast cancer cells), dilute stock to working concentrations in complete media, keeping DMSO below 0.1% v/v to avoid cytotoxicity. G-1 inhibits cell migration with IC50 values of 0.7 nM (SKBr3) and 1.6 nM (MCF7) (paper).
4. In Vivo Administration: For rodent models, such as heart failure or neuropathic pain studies, chronic dosing at 120 μg/kg/day for 14 days has been shown to modulate cardiac fibrosis and neuroinflammatory markers (product_spec).
5. Functional Readouts: Use calcium imaging, western blot for PI3K/PIP3, or migration assays to confirm GPR30 pathway activation (workflow_recommendation).

Protocol Parameters

• Preparation | ≥10 mM in DMSO, gentle warming & ultrasound | All in vitro/in vivo applications | Maximal solubility and stability, prevents precipitation | product_spec
• Cell assay dosing | 0.1–10 nM | Migration, signaling, viability studies | Matches reported IC50/EC50 for GPR30-selective effects | paper
• In vivo dosing | 120 μg/kg/day, 14 days | Rat cardiac/neuropathic pain models | Replicates published efficacy with minimal off-targets | product_spec

Key Innovation from the Reference Study

The reference study by Chen et al. (paper) uncovers a pivotal role for GPR30 in spinal cholecystokinin-positive (CCK+) neurons underpinning neuropathic pain. By demonstrating that GPR30 upregulation in these neurons mediates increased AMPA receptor activity and mechanical allodynia, the study highlights GPR30 as a targetable node for pain modulation. Practical assay translation: when modeling neuropathic pain in CCI mice, incorporating G-1 as a selective GPR30 agonist or antagonist (using chemogenetic or pharmacologic approaches) enables precise dissection of pain circuitry and synaptic plasticity.

Advanced Applications: GPR30 Activation in Cardiovascular and Pain Research

Cardiovascular Research: G-1's ability to reduce brain natriuretic peptide levels, attenuate cardiac fibrosis, and normalize β-adrenergic receptor expression in ovariectomized heart failure models demonstrates its translational utility for cardiac remodeling studies (product_spec). These findings directly complement prior research on rapid estrogen signaling in the heart, as detailed in "G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Cardio...", which benchmarks G-1's quantitative bioactivity and optimal workflows in translational models.

Oncology & Cell Migration: G-1's nanomolar inhibition of breast cancer cell migration highlights its application in dissecting non-classical estrogen signaling in oncology. This extends the evidence base provided in "G-1 (CAS 881639-98-1): Unraveling GPR30-Selective Estroge...", which integrates mechanistic and translational insights for breast cancer and cardiovascular studies.

Neuroscience: The latest reference work reveals GPR30 as a gatekeeper in pain circuits, making G-1 a critical tool for modeling and pharmacologically manipulating neuropathic pain in preclinical systems (paper).

Troubleshooting & Optimization Tips

• Compound Precipitation: If G-1 precipitates upon dilution, ensure the stock is fully dissolved in DMSO and pre-warm the working solution to 37°C. Add DMSO to media slowly and vortex gently to maintain homogeneity (workflow_recommendation).
• DMSO Cytotoxicity: Keep final DMSO concentrations under 0.1% in cell-based assays; higher concentrations can confound results by affecting cell viability (workflow_recommendation).
• Batch Variability: Use validated suppliers such as APExBIO to ensure lot-to-lot consistency and access to technical support for troubleshooting solubility or purity concerns (product_spec).
• Assay Sensitivity: Confirm GPR30 pathway activation by including positive controls (e.g., estradiol for cross-validation) and using orthogonal assays (calcium imaging plus downstream protein readouts) to corroborate findings (workflow_recommendation).
• Storage Stability: Minimize freeze-thaw cycles; store aliquots at -20°C and use within two months for maximal potency (product_spec).

Comparative Advantages: Why Choose G-1 from APExBIO?

G-1 stands apart for its nanomolar potency, exceptional selectivity for GPR30, and proven reproducibility in both cell-based and animal models. APExBIO provides batch-certified, research-grade material with detailed protocols, enabling seamless integration into advanced workflows. Compared to less selective ligands, G-1's low off-target activity (paper) and robust validation across cardiovascular, oncology, and neuroscience domains (paper) make it the preferred reagent for dissecting GPR30-mediated biology.

Why this Cross-Domain Matters, Maturity, and Limitations

The translational bridge from cardiovascular research to pain neuroscience is well-supported by the shared mechanism of GPR30-mediated signaling. The reference study’s demonstration of GPR30's role in spinal neurons that mediate neuropathic pain extends the relevance of G-1–validated in cardiac and cancer models–to neurobiology. However, while G-1 has robust efficacy in preclinical (rodent) settings, further clinical translation requires caution, as in vivo dosing and off-target effects in humans remain to be fully characterized (paper).

Outlook: The Future of GPR30-Targeted Research

Building on the convergence of evidence from cardiovascular, oncology, and pain research, G-1 (CAS 881639-98-1) is poised to accelerate discoveries in rapid estrogen signaling and its disease-modifying potential. The extension of GPR30 modulation into the domain of neuropathic pain, as highlighted by Chen et al., opens new avenues for pharmacological intervention and mechanistic studies in neuronal circuitry. Continued protocol refinement and cross-domain benchmarking will further cement G-1's role as an indispensable tool for translational research (paper).

For detailed specifications and support, visit the G-1 (CAS 881639-98-1), a selective GPR30 agonist product page from APExBIO.